Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Amgen presents positive top-line denosumab results from phase III pivitol trial

July 15, 2008

Tredaptive approved in E.U. for dyslipidemia and primary hypercholesterolemia

July 14, 2008

Pharming reports positive results from open-label studies of Rhucin in HAE

July 14, 2008

Recent Exelixis and Nippon Zoki patents report new treatment options for metabolic disorders

July 14, 2008

Study shows bioequivalence between Insmed's INS-19 and Neupogen

July 14, 2008

Targeting CaMKK2 may be useful for the treatment of obesity and diabetes

July 14, 2008

Proellex reduces pain in phase II clinical trial in moderate to severe endometriosis

July 14, 2008

Ardea moves RDEA-806 into phase IIa proof-of-concept study for gout

July 11, 2008

Sosei completes phase III NorLevo trial in emergency contraception

July 11, 2008

New treatments for obesity disclosed in recent patent literature

July 11, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...